



1633
DOCKET NO: C01039.70035.US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Arthur M. Krieg et al.
Serial No.: 09/669,187
Confirmation No.: 2999
Filed: September 25, 2000
For: IMMUNOSTIMULATORY NUCLEIC ACIDS
Examiner: James Martinell
Art Unit: 1633


RECEIVED

APR 09 2003

TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on the 4 day of April, 2003.


Michelle M. Quinn

Commissioner for Patents
Washington, D.C. 20231

Sir:


Transmitted herewith are the following documents:

- ☒ Information Disclosure Statement
- ☒ PTO Form 1449 with cited references
- ☒ Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 720-3500, Boston, Massachusetts.

A check is not enclosed. If a fee is required, the Commissioner is hereby authorized to charge Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,
Arthur M. Krieg et al., Applicant

By 
Maria A. Trevisan, Reg. No. 48,207
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2211
Telephone: (617) 720-3500

Docket No. C01039.70035.US
Date: April 4, 2003
XNDDX

Docket Number	Serial Number	Filing Date	Inventor(s)
C01039.70067.US	10/300,247	11/20/02	Davis et al.
C01039.70068.US	10/306,522	11/27/02	Krieg et al.
C01039.70069.US	10/314,578	12/9/02	Krieg et al.
C01039.70070.US	10/382,822	3/6/03	Krieg et al.
C01040.70006.US	09/316,199	5/21/99	McCluskie et al.
C01040.70010.US	09/768,012	1/22/01	Davis et al.
C01041.70002.US	09/241,653	2/2/99	Wagner et al.
C01041.70005.US	09/355,254	7/23/99	Wagner et al.
C01041.70010.US	09/786,436	9/3/99	Wagner et al.
C01041.70014.US	09/895,007	6/28/01	Schetter et al.
C01041.70016.US	09/954,987	9/17/01	Bauer et al.
C01041.70019.US	10/140,013	5/6/02	Schetter et al.
C01041.70029.US	10/212,133	8/1/02	Lipford et al.
C01041.70031.US	10/265,072	10/5/02	Lipford
C01041.70035.US	10/373,381	2/24/03	Wagner et al.

Copies of each related application are submitted herewith.

PART IV: Explanation of Non-English Language References and Remarks Concerning Other Information Cited

The following is a concise explanation of the relevance of each non-English language reference listed on the attached form PTO-1449 (modified):

The following are remarks concerning the other information cited:

PART V: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.



DOCKET NO: C01039.70035.US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Arthur M. Krieg et al.
Serial No.: 09/669,187
Confirmation No.: 2999
Filed: September 25, 2000
For: IMMUNOSTIMULATORY NUCLEIC ACIDS
Examiner: James Martinell
Art Unit: 1633

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on the 4 day of April, 2003.


Michelle M. Quinn

Commissioner for Patents
Washington, D.C. 20231

Sir:


Transmitted herewith are the following documents:

- ☒ Information Disclosure Statement
- ☒ PTO Form 1449 with cited references
- ☒ Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 720-3500, Boston, Massachusetts.

A check is not enclosed. If a fee is required, the Commissioner is hereby authorized to charge Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,
Arthur M. Krieg et al., *Applicant*

By 
Maria A. Trevisan, Reg. No. 48,207
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2211
Telephone: (617) 720-3500

Docket No. C01039.70035.US
Date: April 4, 2003
XNDDX

The Applicant hereby makes the following additional information of record in the above-identified application.

The following co-pending applications that may contain subject matter related to this application are enclosed unless the earlier application is identified herein and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application:

Docket Number	Serial Number	Filing Date	Inventor(s)
C01037.70013.US	09/776,479	2/2/01	Bratzler et al.
C01037.70016.US	09/009,634	1/20/98	Hutcherson et al.
C01037.70017.US	09/800,266	3/5/01	Petersen et al.
C01037.70018.US	09/801,839	3/8/01	Bratzler et al.
C01037.70019.US	09/920,313	8/1/01	Peterson et al.
C01037.70021.US	09/949,194	9/7/01	Peterson et al.
C01037.70025.US	10/017,995	12/14/01	Bratzler
C01039.70020.US	09/337,584	6/21/99	Krieg et al.
C01039.70021.US	09/337,619	6/21/99	Krieg et al.
C01039.70022.US	09/337,893	6/21/99	Krieg
C01039.70023.US	09/337,636	6/21/99	Krieg
C01039.70028.US	09/361,575	7/27/99	Krieg
C01039.70029.US	09/415,142	10/9/99	Krieg et al.
C01039.70026.US	09/559,140	4/27/00	Noll et al.
C01039.70041.US	09/655,319	9/5/00	Krieg et al.
C01039.70042.US	09/630,319	7/31/00	Krieg et al.
C01039.70043.US	09/629,477	7/31/00	Krieg et al.
C01039.70044.US	09/672,126	9/27/00	Hartmann et al.
C01039.70048.US	09/818,918	3/27/01	Krieg et al.
C01039.70049.US	09/824,468	04/02/01	Krieg et al.
C01039.70052.US	09/888,326	6/22/01	Weiner et al.
C01039.70053.US	09/931,583	8/16/01	Krieg et al.
C01039.70057.US	09/965,101	9/26/01	Davis et al.
C01039.70058.US	10/023,909	12/18/01	Davis et al.
C01039.70060.US	10/112,653	3/29/02	Krieg et al.
C01039.70061.US	10/161,229	6/3/02	Krieg et al.
C01039.70062.US	10/187,489	7/2/02	Krieg et al.
C01039.70063.US	10/224,523	8/19/02	Krieg et al.
C01039.70065.US	10/272,502	10/15/02	Krieg et al.



DOCKET NO: C01039.70035.US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Arthur M. Krieg et al.
Serial No.: 09/669,187
Confirmation No.: 2999
Filed: September 25, 2000
For: IMMUNOSTIMULATORY NUCLEIC ACIDS
Examiner: James Martinell
Art Unit: 1633


RECEIVED

APR 09 2003

TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on the 7 day of April, 2003.


Michelle M. Quinn

Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed before the mailing date of a first Office Action on the merits in the above-identified case.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).


By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.


Respectfully submitted,
Arthur M. Krieg et al., *Applicant*

By:



Maria A. Trevisan, Reg. No. 48,207
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2211
Telephone: (617) 720-3500

Docket No. C01039.70035.US
Date: April 4, 2003
XNDDX



FORM PTO-6349/A and B (Modified)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

APPLICATION NO.: 09/669,187

ATTY. DOCKET NO.: C01039.70035.US

FILING DATE: September 25, 2000

CONFIRMATION NO.: 2999

APPLICANT: Arthur M. Krieg, et al.



GROUP ART UNIT: 1633

EXAMINER: James Martinell

Sheet 1 of 4

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	A1	5,023,243		Tullis	06-11-1991
	A2	5,248,670		Draper , et al.	09-28-1993
	A3	5,268,365		Rudolph , et al.	12-07-1993
	A4	5,445,938		Hanai , et al.	08-29-1995
	A5	5,488,039		Masor , et al.	01-30-1996
	A6	5,491,088		Hellstrom , et al.	02-13-1996
	A7	5,492,899		Masor , et al.	02-20-1996
	A8	5,585,479		Hoke , et al.	12-17-1996
	A9	5,589,466		Felgner , et al.	12-31-1996
	A10	5,591,721		Agrawal , et al.	01-07-1997
	A11	5,602,109		Masor , et al.	02-11-1997
	A12	5,612,060		Alexander	03-18-1997
	A13	5,663,153		Hutcherson , et al.	09-02-1997
	A14	5,679,647		Carson , et al.	10-21-1997
	A15	5,700,590		Masor , et al.	12-23-1997
	A16	5,705,385		Bally , et al.	01-06-1998
	A17	5,723,130		Hancock , et al.	03-03-1998
	A18	5,723,335		Hutcherson , et al.	03-03-1998
	A19	5,756,097		Landucci , et al.	05-26-1998
	A20	5,780,448		Davis	07-14-1998
	A21	5,786,189		Locht , et al.	07-28-1998
	A22	5,804,566		Carson , et al.	09-08-1998
	A23	5,830,877		Carson , et al.	11-03-1998
	A24	5,837,243		Deo , et al.	11-17-1998
	A25	5,849,719		Carson , et al.	12-15-1998
	A26	5,965,542		Wasan , et al.	10-12-1999
	A27	5,976,567		Wheeler , et al.	11-02-1999
	A28	5,981,501		Wheeler , et al.	11-09-1999
	A29	5,985,847		Carson , et al.	11-16-1999
	A30	6,013,639		Peyman , et al.	01-11-2000
	A31	6,027,726		Ansell	02-22-2000
	A32	6,110,745		Zhang, et al.	08-29-2000
	A33	6,174,872		Carson , et al.	01-16-2001
	A34	6,194,388	B1	Krieg, et al.	02-27-2001
	A35	6,207,646	B1	Krieg, et al.	03-27-2001
	A36	6,214,806	B1	Schwartz, et al.	04-10-2001
	A37	6,218,371	B1	Krieg, et al.	04-17-2001




A38	6,239,116	B1	Krieg, et al.	05-29-2001
A39	6,339,068	B1	Davis, et al.	01-15-2002
A40	6,406,705	B1	Davis, et al.	06-18-2002
A41	6,429,199	B1	Krieg, et al.	08-06-2002
A42	2002/0064515	A1	Davis, et al.	05-30-2002

FOREIGN PATENT DOCUMENTS


Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
	B4	EP	0 302 758	B1	New England Medical Center Hospitals, Inc.	03-16-1994	
	B5	EP	0 468 520	A2	Mitsui Toatsu Chemicals, Inc.	01-29-1992	
	B6	WO	91/12811	A1	Isis Pharmaceuticals, Inc., Et Al.	09-05-1991	
	B7	WO	92/03456	A1	Isis Pharmaceuticals, Inc.	03-05-1992	
	B8	WO	92/18522	A1	The Salk Institute For Biological Studies,	10-29-1992	
	B9	WO	92/21353	A1	Genta Incorporated	12-10-1992	
	B10	WO	94/19945	A1	Isis Pharmaceuticals, Inc.	09-15-1994	
	B11	WO	95/05853	A1	The Regents Of The University Of CA	03-02-1995	
	B12	WO	95/26204	A1	Isis Pharmaceuticals, Inc.	10-05-1995	
	B13	WO	96/02555	A1	The University Of Iowa Research Foundation	02-01-1996	
	B14	WO	96/13277	A1	The Regents Of The University Of CA	05-09-1996	
	B15	WO	96/14074	A1	The Regents Of The University Of CA	05-17-1996	
	B16	WO	96/24380	A1	ICN Pharmaceuticals, Inc.	08-15-1996	
	B17	WO	96/35782	A1	Applied Research Systems, et al..	11-14-1996	
	B18	WO	98/14210	A1	The Regents Of The University Of CA	04-09-1998	
	B19	WO	98/16247	A1	The Regents Of The University Of CA	04-23-1998	
	B20	WO	98/18810	A1	The University Of Iowa Research Foundation	05-07-1998	
	B21	WO	98/29430	A1	Tam	07-09-1998	
	B22	WO	98/51278	A2	Inex Pharmaceuticals Corporation	11-19-1998	
	B23	WO	98/55495	A2	Dynavax Technologies Corporation	12-10-1998	
	B24	WO	98/55609	A1	The Regents Of The University Of CA	12-10-1998	
	B25	WO	99/33493	A1	Inex Pharmaceuticals Corporation	07-08-1999	
	B26	WO	99/52549	A1	Smithkline Beecham Biologicals S.A.,	10-21-1999	
	B27	WO	99/62923	A2	Dynavax Technologies Corporation	12-09-1999	
	B28	WO	00/03683	A2	Inex Pharmaceuticals Corporation	01-27-2000	
	B29	WO	00/14217	A2	CPG Immunopharmaceuticals Gmbh	03-16-2000	
	B30	WO	00/16804	A1	Dynavax Technologies Corporation	03-30-2000	
	B31	WO	00/20039	A1	The Regents Of The University Of CA	04-13-2000	
	B32	WO	00/21556	A1	Dynavax Technologies Corporation	04-20-2000	
	B33	WO	00/62787	A1	The Regents Of The University Of CA	10-26-2000	
	B34	WO	01/02007	A1	The Regents Of The University Of CA	01-11-2001	
	B35	WO	01/12223	A2	Dynavax Technologies Corporation	02-22-2001	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
---------------------	---------	---	-------------------



C15	AGRAWAL, et al., <i>Clin. Pharmacokinet</i> , 28(1):7-16, 1995		
C16	AGRAWAL, <i>Tibtech</i> , 14:376-387, 1996		
C17	ARKWRIGHT, et al. <i>J Allerg Clin Immunol</i> . 107:531-4, 2001		
C18	AZAD, et al., <i>Antimicrobial Agents and Chemotherapy</i> , 37:1945-1954, (1993)		
C19	AZUMA, et al., <i>Kekkaku</i> , 67(9):625-631, (45-55) 1992		
C20	BALLAS, et al., <i>J Immunol</i> 157(5):1840-5, 1996		
C21	BATES, et al. <i>J Biol Chem</i> 274:26369-77, 1999		
C22	BENIMETSKAYA, et al. <i>Nucleic Acids Res.</i> 25:2648-2656, 1997		
C23	BISHOP, et al. <i>J. Biol. Chem.</i> 271:5698-5703, 1996		
C24	BLAXTER et al., <i>Mol. and Biochem. Parasitology</i> , 77:77-93		
C25	BRANDA et al., <i>Biochemical Pharmacology</i> , 45(10):2037-2043, 1993		
C26	BRANDA, et al., <i>J. Lab Clin Med</i> 128(3):329-38, 1996		
C27	BROIDE & RAZ <i>Intl Arch Allerg & Immunol.</i> 118:453-456, 1999		
C28	BRUNNER, et al., <i>J Immunol.</i> 165:6278-6286, 2000		
C29	BURGESS, et al., <i>Proc. Natl. Acad. Sci USA</i> 92(9):4051-5, 1995		
C30	CARTER, et al. <i>Intl J Immunopharmacol.</i> 13:69-76, 1991		
C31	CHACE, et al., <i>Clinical Immunology and Immunopathology</i> , (1993), 68(3):327-332		
C32	CONSTANT, et al., <i>Annu. Rev. Immunol.</i> , 15:297-322, 1997		
C33	CONSTANT, et al., <i>Science</i> , 264:267-70, 1994		
C34	COWDERY, et al., <i>J Immunol</i> 156(12):4570-5, 15 1996		
C35	COWSERT, et al. <i>Antimicrobial Chemother.</i> 37:171-77, 1993		
C36	DAPIC, et al. <i>Proc. AACR</i> , pp. 42, March 2001		
C37	DIAMANSTEIN, et al. <i>Euro J Immunol.</i> 8:896, 1978		
C38	ELKINS, et al. <i>J. Immunol.</i> 162:2291-2298, 1999		
C39	EWEL, et al., <i>Cancer Res.</i> , 52(11):3005-10, 1992		
C40	FUJIEDA, et al., <i>Anticancer Res.</i> , 12:1941-1946, 1992		
C41	GAO, et al., <i>Mol. Pharmacol.</i> (1992), 41, 223-229		
C42	GOLD, et al., <i>Annual Rev. Biochem.</i> 64:763-97, 1995.		
C43	HADDEN J et al., <i>JAMA</i> , (1992) 268:20:2964-2969		
C44	HADDEN J et al., <i>TIPS</i> , (1993), 141:169-174		
C45	HAHM, et al. <i>Intl J. Immunopharmacol.</i> 16:217, 1994		
C46	HALPERN MD et al., <i>Cell Immunol</i> 167(1):72-8, 1996		
C47	HARRINGTON, et al. <i>Infection Immunity</i> 24:160, 1970		
C48	HARTMANN, et al. <i>Antisense Nucleic Acid Drug Dev</i> , 6:291, 1996		
C49	HATZFELD J., <i>J. Exp. Med.</i> , (1991) 174:925-929		
C50	HERTL, et al., <i>J. Invest. Dermatol.</i> , 104:813-818, 1995.		
C51	HORNER, et al. <i>Springer Semin Immunopathol</i> , 22(1-2):133-46, 2000		
C52	HORSPOOL, et al., <i>J. Immunol</i> , 160, 2706-2714, 1998		
C53	HUANG, et al., <i>Infection and Immunity</i> , 67(12):6257-6263 (1999)		
C54	HUGHES, et al. <i>Antisense Res Dev</i> 4:211-15, 1994		
C55	ISHIKAWA, et al., <i>J Immunol</i> 150(9):3713-27, 1993		
C56	IVERSEN, et al., <i>Antisense Research and Development</i> , (1994), 4:43-52		
C57	JAKOB, et al., <i>Int. Arch Allergy Immunol.</i> , 118(2-4):457-61, 1999		
C58	JAKOB, et al., <i>J. Immunol.</i> , 161(6):3042-9, 1998		
C59	JOHNSON, et al. <i>Immunopharmacol Infect Disease</i> , 291-301, 1987		
C60	KARLIN, et al., <i>J. of Virol.</i> , 2889-2897, 1994		
C61	KATAOKA, et al., <i>Jpn. J. Med. Sci. Bio.</i> , 43:171-189 (1990)		



C62	KERN, et al. <i>Antimicrobial Agent Chemother.</i> 7:793, 1975		
C63	KIMURA Y et al., <i>J. Biochem.</i> , 116(5):991-994, 1994		
C64	KLOC, et al., "Interleukin-2 antisense oligonucleotides inhibit in vitro functions of T cells." <i>FASEB J.</i> , Vol. 5, pp. A973, abstract no. 3497, 1991.		
C65	KROWN, S.E., <i>Semin Oncol.</i> , 13(2):207-17, 1986		
C66	LEE, et al. <i>Transplantation</i> , 62:1297-1301, 1996		
C67	LEVINE, et al. <i>Cancer Treatment Repts.</i> 62:1907, 1978		
C68	LEVY, et al. <i>J Infect Disease</i> , 133:A256, 1976		
C69	LU, et al., <i>Clin. Exp. Immunol.</i> , 115:335-341, 1999		
C70	MACAYA, et al. <i>Proc Natl Acad Sci USA</i> 90:3745-9, 1993		
C71	MASHIBA, et al., <i>Jpn. J. Med. Sci. Biol.</i> , 41:197-202, 1988		
C72	MASTRANGELO, et al., <i>Seminars in Oncology</i> . 23(1):4-21, Feb 1996		
C73	MATSON S and KRIEG AM, <i>Antisense Res Dev</i> 2(4):325-30, Winter 1992		
C74	MATSUKURA, et al. <i>Proc Natl Acad Sci USA</i> 86:4244-48, 1989		
C75	MESSINA et al., <i>Cellular Immunology</i> , 147(1):148-157, 1993		
C76	NYCE and METZGER, <i>Nature</i> 385:721-725, 1997		
C77	PARKER, et al. <i>Cancer Gene Therapy</i> . 3:175, 1996		
C78	PETERSEN, et al., <i>Bio. Pharm.</i> , 47(1):127-128, 1994		
C79	PISETSKY DS, <i>Antisense Res Dev</i> , 5(3):219-225 (1995)		
C80	PISETSKY DS, <i>J Immunol</i> 156(2):421-3, 1996		
C81	POTTRATZ, et al., <i>J. Clin. Invest.</i> , 93(3):944-50, 1994		
C82	RAMANATHAN, et al. <i>J Biol Chem</i> 269:24565-74, 1994		
C83	RAMANATHAN, et al. <i>Transplantation</i> , 57:612-15, 1994		
C84	RAZ, et al., <i>Proc Natl Acad Sci USA</i> 93(10):5141-5, (1996)		
C85	ROMAN M et al., <i>Nat Med</i> 3(8):849-54, (1997)		
C86	ROUSH, et al. <i>Science</i> , 276:1193, 1997		
C87	SATO et al., <i>Science</i> , 273:352-354, 1996		
C88	SHIRAKAWA, et al., <i>Science</i> 275(5296):77-9, (1997)		
C89	SIN, et al, <i>J. of Virol.</i> , 73(1):501-509, 1999		
C90	SIN, et al., <i>J. of Immunol.</i> , 162:2912-2921, 1999		
C91	STULL et al., <i>Pharmaceutical Res.</i> , 12(4):465-483, 1995		
C92	TALMADGE, et al., <i>Cancer Res.</i> 45(3):1058-65, 1985		
C93	TSUJI, et al., <i>J. of Immunol.</i> , 158:4008-4013, 1997		
C94	WANG, et al. <i>Proc. Natl Acad. Sci. USA</i> , 90:4156-4160, 1993		
C95	WILTROUT, et al., <i>J. Biol. Res. Mod.</i> , 4(5):512-7, 1985		
C96	WYATT, et al. <i>Proc Natl Acad Sci USA</i> , 91:1356-60, 1994		

EXAMINER

DATE CONSIDERED

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]